Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BCRX 
BioCryst Pharmaceuticals Inc (BCRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: BCRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $17.2
1 Year Target Price $17.2
| 6 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.12% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.66B USD | Price to earnings Ratio - | 1Y Target Price 17.2 |
Price to earnings Ratio - | 1Y Target Price 17.2 | ||
Volume (30-day avg) 12 | Beta 1.13 | 52 Weeks Range 6.01 - 11.31 | Updated Date 09/15/2025 |
52 Weeks Range 6.01 - 11.31 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -6.41% | Operating Margin (TTM) 18.23% |
Management Effectiveness
Return on Assets (TTM) 7.46% | Return on Equity (TTM) -1925.37% |
Valuation
Trailing PE - | Forward PE 21.98 | Enterprise Value 2103608601 | Price to Sales(TTM) 2.98 |
Enterprise Value 2103608601 | Price to Sales(TTM) 2.98 | ||
Enterprise Value to Revenue 3.77 | Enterprise Value to EBITDA 33.16 | Shares Outstanding 209920000 | Shares Floating 207686877 |
Shares Outstanding 209920000 | Shares Floating 207686877 | ||
Percent Insiders 1.26 | Percent Institutions 95.86 |
Upturn AI SWOT
BioCryst Pharmaceuticals Inc
Company Overview
History and Background
BioCryst Pharmaceuticals Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Initially focused on structure-guided drug design, it has evolved into a commercial-stage biotechnology company focusing on oral medicines for rare diseases.
Core Business Areas
- Oral, Small-Molecule Medicines: BioCryst discovers, develops, and commercializes novel, oral small-molecule medicines that treat rare diseases where significant unmet medical needs exist.
- Complement System Inhibition: The company's primary focus is on inhibiting the complement system, a part of the immune system, to treat diseases like hereditary angioedema (HAE).
Leadership and Structure
BioCryst is led by Jon Stonehouse (CEO). The organizational structure is typical of a biotechnology company, with departments focused on research, development, commercialization, and corporate functions.
Top Products and Market Share
Key Offerings
- ORLADEYO (berotralstat): ORLADEYO is an oral, once-daily therapy for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years and older. Its market share has been growing steadily since launch, challenging injectable treatments. Competitors include Takeda (TAREDI) with TAKHZYRO, CSL Behring with HAEGARDA and BERINERT, and BioMarin (BMRN) with ROCTAVIAN.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The rare disease market offers high potential due to unmet medical needs and orphan drug designation incentives.
Positioning
BioCryst is positioned as a leader in oral therapies for rare diseases, particularly HAE. Its competitive advantage lies in its oral formulation and targeted approach to complement system inhibition.
Total Addressable Market (TAM)
The HAE market is estimated to be worth several billion dollars annually. BioCryst is well-positioned to capture a significant portion of this TAM with ORLADEYO, particularly as it gains wider adoption and expands into new markets.
Upturn SWOT Analysis
Strengths
- Oral formulation of ORLADEYO
- Targeted approach to complement system inhibition
- Experienced management team
- Strong intellectual property protection
Weaknesses
- Reliance on a limited number of products
- High R&D expenses
- Competition from established injectable therapies
- Potential for clinical trial setbacks
Opportunities
- Expansion into new markets and indications
- Potential acquisitions or partnerships
- Advancements in drug delivery technologies
- Increasing awareness of rare diseases
Threats
- Regulatory hurdles
- Competition from new therapies
- Pricing pressures
- Patent expirations
Competitors and Market Share
Key Competitors
- TAREDI
- CSL
- BMRN
Competitive Landscape
BioCryst's oral formulation of ORLADEYO gives it a competitive edge over injectable therapies. However, it faces competition from established players with strong market presence and pipeline products.
Growth Trajectory and Initiatives
Historical Growth: BioCryst's historical growth has been driven by its successful development and commercialization of ORLADEYO.
Future Projections: Analyst estimates project continued revenue growth for BioCryst, driven by ORLADEYO sales and potential expansion into new indications. Profitability is expected to improve in the coming years.
Recent Initiatives: Recent strategic initiatives include expanding ORLADEYO's market reach, investing in research and development of new therapies, and exploring potential acquisitions and partnerships.
Summary
BioCryst is a growing biotechnology company driven by the success of its oral HAE therapy, ORLADEYO. Its strong product pipeline and focus on rare diseases provide growth potential, but it faces competition and regulatory risks. Overall, the company is in a relatively strong position with a solid footing in a growing market, but they will need to stay vigilant regarding market shifts and future pipeline development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioCryst Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 1994-03-03 | CEO & Executive Director Mr. Jon P. Stonehouse | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 580 | Website https://www.biocryst.com |
Full time employees 580 | Website https://www.biocryst.com | ||
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.